Lilly opens technology and innovation site in Hyderabad

IMT News Desk
IMT News Desk
· 2 min read

The centre creates opportunities for local talent and advances Hyderabad’s biotech ecosystem

Eli Lilly and Company (India) announced the opening of its new technology and innovation site in Hyderabad, a new strategic hub for advanced digital and technology capabilities that will improve efficiency across Lilly’s global operations. By focusing on areas such as artificial intelligence (AI), automation, cloud computing, and software product engineering, the site will contribute to solving some of the world’s most pressing health challenges while also creating growth opportunities for local talent.

Located in Gachibowli, Lilly’s Hyderabad site spans approximately 220,000 square feet across four floors within the Phoenix Equinox building. Lilly has already onboarded 100 professionals at the Hyderabad facility and plans to expand the headcount to 1,500 over the next few years. The facility was officially inaugurated by Diogo Rau, Executive Vice President and Chief Information and Digital Officer of Eli Lilly and Company, alongside the Hon’ble Chief Minister of Telangana, A Revanth Reddy and D Sridhar Babu, Minister for IT, Electronics & Communications, Industries & Commerce, and Legislative Affairs, Government of Telangana. Sanjay Kumar, IAS, Special Chief Secretary, Industries and Commerce Department, was also present at the event.

Reddy, Chief Minister of Telangana, said, “We are delighted to welcome Lilly to Hyderabad’s growing life sciences ecosystem. The inauguration of this new site further reinforces the city’s position as a global hub for healthcare innovation, built on scientific excellence, skilled talent, and international collaboration. The Government of Telangana remains committed to fostering an environment where pioneering companies like Lilly can thrive and deliver meaningful impact both in India and globally.”

Sridhar Babu, Minister for Information Technology, Electronics & Communications, Industries & Commerce and Legislative Affairs, Telangana, added, “Hyderabad is rapidly emerging as a global epicentre for digital innovation, and Lilly’s new site inauguration is a strong validation of that momentum. This investment reflects the transformative impact of technology on healthcare. Telangana remains committed to enabling future-focused partnerships that drive economic growth and advance digital health solutions for the world.”

“The inauguration of our Hyderabad site reflects our long-term commitment to India and our intent to strengthen our presence in the region,” said Diogo Rau, Executive Vice President and Chief Information and Digital Officer, Eli Lilly and Company.

Read Next

Sun Pharma receives DCGI approval to manufacture, market generic semaglutide injection in India for chronic weight management
Corporate
January 27, 2026

Sun Pharma receives DCGI approval to manufacture, market generic semaglutide injection in India for chronic weight management

Company to launch product after the expiry of semaglutide patent in India Sun Pharmaceutical Industries has received approval from the Drugs Controller General of India (DCGI) to manufacture and market a generic version of semaglutide injection. Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is indicated for chronic weight management in adults as an adjunct to […]
Article by: IMT News Desk
Lupin receives highest ESG rating from CDP for climate change and water security
Corporate
January 27, 2026

Lupin receives highest ESG rating from CDP for climate change and water security

The recognition affirms Lupin’s position among distinguished global leaders who champion sustainability and transparency at the highest level Lupin has received the highest ‘A’ leadership rating from Climate Disclosure Project (CDP) for its exceptional accomplishments in Climate Change and Water Security. The recognition affirms Lupin’s position among distinguished global leaders who champion sustainability and transparency […]
Article by: IMT News Desk
AstraZeneca Pharma India receives CDSCO approval for breast cancer drug
Corporate
December 19, 2025

AstraZeneca Pharma India receives CDSCO approval for breast cancer drug

Dato-DXd is a specifically engineered antibody drug conjugate that targets TROP2, a protein frequently overexpressed in breast cancer AstraZeneca Pharma India announced that the Central Drugs Standard Control Organisation (CDSCO) has granted regulatory approval to import, sell, and distribute Datopotamab Deruxtecan (Dato-DXd) in India. The approval reflects AstraZeneca’s focus on bringing to life-changing medicines at […]
Article by: IMT News Desk
Novo Nordisk launches Ozempic in India
Corporate
December 12, 2025

Novo Nordisk launches Ozempic in India

Ozempic is a once-weekly GLP-1 RA (receptor agonist) indicated as an adjunct to diet and exercise for adults living with uncontrolled type 2 diabetes mellitus Novo Nordisk announced the launch of Ozempic (injectable semaglutide) in India. Ozempic is a once-weekly GLP-1 RA (receptor agonist) indicated as an adjunct to diet and exercise for adults living […]
Article by: IMT News Desk